Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921392 | 0.83 | CYP3A4 (0.42) | CYP3A4TGFBR1METAP2BRD4CNR2 | |
| SCHEMBL12059073 | 0.83 | NPC1 (0.40) | CYP3A4TGFBR1METAP2BACE1CTSD | |
| SCHEMBL6922413 | 0.81 | NPC1 (0.43) | CYP3A4TGFBR1METAP2PIK3CDPIK3CA | |
| SCHEMBL6920771 | 0.81 | KDM4E (0.39) | CYP3A4TGFBR1METAP2BACE1CTSD | |
| SCHEMBL14239134 | 0.80 | KMT2A (0.39) | CYP3A4TGFBR1METAP2BACE1CTSD | |
| SCHEMBL9994570 | 0.80 | POLB (0.47) | — | |
| SCHEMBL6921660 | 0.79 | CYP3A4 (0.38) | CYP3A4TGFBR1METAP2BACE1CTSD | |
| SCHEMBL6923262 | 0.79 | RAB9A (0.46) | CYP3A4 | |
| SCHEMBL6921117 | 0.78 | CYP3A4 (0.37) | CYP3A4TGFBR1METAP2BACE1CTSD | |
| SCHEMBL14239415 | 0.78 | RAB9A (0.41) | CYP3A4TGFBR1METAP2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | CYP3A4 4447/4885TGFBR1 3543/4885METAP2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.